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lntcrlcukind (IL-Q belongs to a family of small, structurally related cytokincs imilar to platclct factor 4. It is produced by phagocytes and 
mcsenchymal cells exposed to inflammatory stimuli (e.g. interlcukin-I or tumor necrosis her) and activales ncutrophils inducing chcmotaxis, 
cxocytosis and the respiratory burst. In vivo, IL-8 elicits a massive neutropbil accumulation at thz site or injection. Five nuutrophil-activating 
cytokines imilar to IL-8 in structure and function have been identified recently. IL-8 and the related cytokincs are produced in several tissues upon 
infection, inflammation, ischcmia, trauma etc., and are thought o bc the main cause of local ncutrophil accumul;ition. 
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1. INTRODUCTION 
The accumulation of neutrophil eukocytes in a tissue 
is the hallmark of inflammation, a defence reaction to 
infection or other injury, with participation of blood, 
blood vessel and tissue elements. The neutrophils are 
recruited from the blood by chemotactic stimuli that 
direct their migration through the vessel wall to the 
affected site. 
Interleukin-8 (lL-8) was identified in 1987 as a novel 
type of neutrophil-activating cytokine [l]. Today we 
know its sequence and 3D structure, the sequence and 
binding properties of its receptors, and the profile of 
biological activity. Several additional cytokines related 
to IL-8, but arising from different genes have also been 
characterized. IL-8 and related cytokines are released 
by phagocytes and a wide variety of tissue cells upon 
exposure to inflammatory stimuli. They are the main 
tissue-derived chemoattractants for neutrophils. 
fide bridges. It is resistant o plasma peptidases, heat, 
pM extremes and other denaturing treatments, but is 
rapidly inactivated when the disulfide bonds are re- 
duced [l]. Nuclear magnetic resonance spectroscopy 
and X-ray crystallography studies indicate that IL-8 
forms a dimer [2]. The monomer has a short, confor- 
mationally flexible N-terminal domain that is anchored 
by the two disulfide bonds to a core structure consisting 
of three antiparallel b-strands followed by a terminal 
a-helix (Fig. 2). 
2. PROPERTIES 
2.1. SrnKrure 
IL-8 was originally recognized as a neutrophil-acti- 
vating protein on the basis of two in-vitro effects, che- 
motaxis and the release of granule enzymes [I]. These 
effects uggested that IL-8 ~8s a novel type of chemoat- 
tractant, and for this reason it was compared exten- 
sively with well established chemotactic agonists, such 
as CSa, filet-Leu-Phe, platelet-activating factor (PAF) 
and leukotriene BA (LTB,). These stimuli induce three 
main responses in neutrophils: (i) shape change and 
directional migration, (ii) exocytosis of storage proteins, 
and (iii) the respiratory burst. 
lL-8 is generated as a precursor of 99 amino acids and 
is secreted after cleavage of a signal sequence of 20 
residues. N-terminal extracellular processing of the ma- 
ture form yields several biologically active variants (Fig. 
1). The predominant variant consists of 72 amino acids 
and has a molecular weight of 8,383. It is a basic protein 
(PI 8.3) and contains four cysteines that form two disul- 
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The shape cltmge reflects the activation of the con- 
tractile system and enables the neutrophils to adhere to 
cndothelial cells and to migrate. In ncutrophil suspen- 
sions, the shape change can be monitored in a laser 
nephclome~er asa transient rise in light transmission, 
which reflects the decrease in cell body volume conse- 
quent to the formation of large and thin lamellipodia 
[3]. The shape-dependent transmission increase in re- 
sponse to IL-8 is virtually instantaneous and is similar 
in kinetics and extent to that observed with CSa OF 
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fMet-Leu-Phe. When the response of the cells is syn- 
chronized by prestimulation, the transmission changes 
induced by chemoattractants including IL-S show regu- 
lar oscillations that correlate with the assembly and 
disassembly of fllamentous actin, and are thought to 
reflect he protrusion and retraction of lamellipodia [3]. 
E_socylosis leads to the release of soluble storage pro- 
teins and the remodeling of the neutrophil plasma mem- 
brane by fusion with the storage organelles. IL-8 trig- 
gers the exocytosis of specific granules and secretory 
vesicles. Upon pretreatment with cytochalasin B, these 
responses are markedly enhanced, and the release of 
enzymes from the azurophil granules, e.g. elastase, is 
observed in addition. IL-8 dependent SM$K~ ntmbrme 
rmrodehg during exocytosis leads to the expression of 
adhesion molecules, CD I I b/CD I S (complement recep- 
tor type 3), CD1 It/CD 18 (pl50,95) and complement 
receptor type I [4,5]. This upregulation markedly en- 
hances the ability of neutrophils to adhere to endothe- 
lial cells and to the extracellular matrix. 
The respircrtory bum is characteristic for stimulated 
phagocytes, Like other chemoattractants IL-S elicits the 
rapid and transient activation of the NADPH-oxidase, 
leading to superoxide and HIOz formation. In terms of 
duration and intensity the respiratory burst induced by 
IL-8 is considerably weaker than that observed with 
flvIet-Leu-Phe or C5a, but more pronounced than that 
induced by PAF or LTB, [ 1, 61. 
IL-8 receptors are coupled to BorrkteCla pcrrtrssis 
toxin-sensitive GTP-binding proteins. Signal transduc- 
tion depends on the activation of a phospholipase C
specific for phosphatidylinositol 4,5-bisphosphate, 
which delivers two second messengers, IP3 and dia- 
cylglycerol. 1P3 induces a rise in cytosolic free calcium. 
and diacylglycerol activates protein kinase C. ADP-ri- 
bosylation of GTP-binding proteins by pertussis toxin, 
depletion of mobilizable calcium, and exposure to pro- 
tein kinase inhibitors or to wortmannin can be used to 
modulate signal transduction and to influence shape 
change, exocytosis and the respiratory burst [7]. The 
responses of neutrophils to TL-8 and fMet-Leu- Phe are 
modified in a similar way by such treatments, indicating 
that they are controlled by a comparable mechanism [8]. 
EGAVPLRSARELREQ~... 79 aa 
AVPLRSAKRLRSQ~... 77 aa 
SAKELRiZQQ... 72 aa 
RELREQC... 70 aa 
ELRCQE.. . 69 aa 
Fig. l I N tcrmini of the naturally occurring, biologically active forms 
or IL-S. 
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2.4. Efjkcts itt viva 
Studies in rabbits showed massive neutrophil accu- 
mulation and plasma exudation upon intradermal injec- 
tion of human IL-8. The effect was rapid and long- 
lasting. The cellular infiltration was already significant 
after I5 min, and the immigration of neutrophils re- 
mained detectable for up to 10 h [9,10]. Resistance to 
inactivation and slow clearance from the injection site, 
possibly due to charge interaction with acidic tissue 
matrix components, could explain the long duration of 
action. Comparable responses to human IL-8 were ob- 
served in mice, rats, guinea pigs and dogs. Studies in 
human skin showed the same kind of inflammatory 
reaction with exclusive infiltration of neutrophils in par- 
ticular around venules. Lymphocyte numbers were not 
increased, and no basophils, eosinophils or monocytes 
were found. IL-8 caused no wheal and Rare, itching or 
pain, suggesting that it does not induce histamine re- 
lease from skin mast cells [ 11,121. 
3. UBIQUITOUS PRODUCTlON 
IL-8 was originally identified in the medium of 
human blood monoq :es cultured in the presence of 
endotoxin, phorbol esters or lectins [I]. It was soon 
realized, however, that many different cells have the 
Fig. 2. Ribbon rcprescntation of the polypeptidc backbone of the 69 
amino acid form of IL-8 as a dimer. The N-terminal region (bottom 
right, top left) is anchored to the rest of the molecule by two disulfide 
bridges, An N-terminal loop follows the frst two cystcines and leads 
into the central/Sstrand thut interfaces with the other monomer. After 
two additionalp-strands, the structure ends with a C-terminal a-helix. 
Diffcrcnt shading was used for the monomers. 
Volume 307, number I FEBS LETTERS July 1992 
l3TL-8 SAKELRCQCIKTISKPPHPKFZKELRV~ESGPSC 
NAP-Z A. . ..Mm...T.G-f...N.QS.E..GK.T.. 
GROa ASV.T...*.*LQ.LQG-I...N.QSYbl.KSP..,. 
GROR APL.'l?...*.*LQ.LQG-I.L.N.QSVK.K3P.... 
GROy ASVVT...a..LQ.LQG-T.L.N.QSVN.RSP.... 
ENA- AGBAAAVLR...*V*LQ.TQG-V...M.SN.Q.FAI..Q* 
PF-4 EAEEDGD.Q*L*V..T.Q-VR.RH.TS.E..KA...* 
IPICI VPLSRTV.rT..SfSNQ.VN.RSLEK.EiX.PASQFm 
IL-8 SAKELRCQCIKTISKPPHPKFIKELRYIBSGPnC 
Fig, 3. N-tcrmiaal sequences of proteins related to lt-8 (72 amino acid form) aligned according IO the cystcincs. Note that the ELR (Glu-Lcu-Arg) 
sequence preceding the first cysuinc is shared by all proteins with ncutrophil-activating proprtim. 
ability to produce IL-8 when appropriately stimulated. 
The expression of IL-8 mRNA and the release of the 
biologically active cytokine was observed in endothelial 
cells, fibroblasts from different tissues, keratinocytes, 
synovial cells, chondrocytes, everal types of epithelial 
cells as well as some tumor cells [ 1,131. Interestingly, 
even neutrophils can synthesize IL-8 [14], and may thus 
intensify their own recruitment to sites of inflammation. 
Interleukin-1 (IL-l) and tumor necrosis factor (TNF) 
are clearly the most important stimuli, since they were 
found to induce IL-8 expression and secretion in all cells 
studied so far [1 51. Endotoxin is very effective on phag- 
ocytes and endothelial cells, but inactive on mesenchy- 
mal cells, klonocytes and macrophages generate IL-8 
upon stimulation with IL-la, IL-l,& TNFa, IL-3, GM- 
CSF, endotoxin, lectins, phorbol esters, immune com- 
plexes and phagocytosis [16]. Opsonized particles are 
also a prime stimulus for IL-8 production by neutro- 
phils [ 141. 
4. REDUNDANCY 
lL-8 belongs to a family of sequence-related 8-10 
kDa proteins characterized by the conserved position of 
their four cysteine residues. Platelet basic protein, con- 
nective tissue-activating peptide III and platelet factor 
4, which are components of the a-granules of blood 
platelets, and y-interferon inducible protein (IPlO) were 
known before IL-S. They differ from IL-8 by their lack 
of neutrophil-activating properties [l]. Several proteins 
that share a!ructural and biological similarity to IL-8 
were discovered more recently, Neutrophil-activatitzg 
peptide- 2 (NAP-2) derives from the N-terminal proc- 
essing of platelet basic protein or connective tissue-acti- 
vating peptide-III, which are released from stimulated 
platelets [17]. GROa designates a protein that was orig- 
inally described as melanoma growth stimulatory activ- 
ity (MGSA) on the basis of its effects on certain mela- 
noma cell lines [18], and was later shown to be a power- 
ful neutrophil chemoattractant [19]. Two related mole- 
cules, GROP and GROy, were found subsequently [20]. 
The three GRO proteins have about 90% sequence iden- 
tity and similar neutrophil-activating properties (De- 
wald and Clark-Lewis, unpublished results), Finally, an 
epithelial cell derived neutrophil-activating peptide, 
EN’A-78, was discovered in the cultures of type-11 alve- 
olar cells [21]. 
IL-8 and its five related chemotactic ytokines arise 
from different genes clustered on chromosome 4 [22]. In 
pathological conditions, it is likely that several of them 
are generated concomitantly as suggested by experi- 
ments with type-11 lung epithelial cells which release 
IL-8, GROa and GROy in addition to ENA- [21]. It 
has been shown in several laboratories that the expres- 
sion of IL-8 and GROa is regulated in a similar way in 
a variety of different cells [IS]. On the other hand, differ- 
ential expression in dependence of the tissue and the 
stimulus has been reported for the three gro genes [20]. 
The existence of so many structurally related proteins 
with comparable neutrophil-activating effects is aston- 
ishing. It may be taken to suggest hat the function of 
IL-8 is so important that several back-up genes have 
evolved. It is conceivable, however, that these different 
cytokines may have distinguishing biological properties 
apart from their common effects on neutrophils. 
5. IL-8 RECEPTORS 
Homologous desensitization was used initially to 
demonstrate that IL-S acts via a selective receptor. It 
was shown that neutrophils remain responsive to IL-8 
after stimulation with fMet-Leu-Phe, CSa, PAF or 
LTB,, and that IL-8 does not desensitize the cells 
against hese other chemoattractants [23]. IL-8 recep- 
tors on human neutrophils and myeloid cell lines were 
then demonstrated in several independent studies. In 
general agreement with their results, we have shown 
that human neutrophils possess on average G4,KK.l f 
14,000 receptors with an apparent Kd of 0. I8 10.07 nM 
[24]. Competition for the binding of radiolabelled IL-8 
was obtained not only with unlabelled IL-S, but also 
with NAP-2 and GROa. These studies revealed the exis- 
tence of two types of receptors: one with high affmity 
for all three ligands (& 0.1-0.3 nM). and one with the 
same afhnity for IL-S, but lower affinity for NAP-2 and 
GROa (& 100-l 30 nM) f24]. Two membrane proteins 
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that bind lL-8, NAP-2 and GROa were found in 
crosslinking experiments inagreement with Samanta et 
al. [2S]. Furthermore cross-desensitization i dicated 
that NAP-:! and GROa [24] as well as ENA- [21], 
GRO,8 and GROy (Dewald and Clark-Lewis, unpub- 
lished results) share the receptors with IL-S. 
5.1, Receptor structrrre 
A major advance in the understanding of neutrophil 
activation was the demonstration that chemotactic ag 
onist receptors belong to the seven-transmembrane-do- 
main type, Soon after the pioneering work of Boulay et 
al. [26] on the fMet-Leu-Phe receptor, two IL-8 receptor 
cDNAs were cloned and shown to code for similar in- 
tramembrane molecules [27,28]. These observations 
provided the last piece of evidence that IL-S, despite its 
name, must be regarded as a chemotactic agonist. Ex- 
tensive biological experimentation had already strongly 
indicated that the effects of IL-8 on neutrophils were 
typical for chemoattractants [I],and the recent informa- 
tion on the receptor sequence showed that this inrerpre- 
tation was correct. An important consequence of the 
finding that IL-8 acts through a chemoattractant, rather 
than a cytokine, or growth factor-type receptor is that 
natural antagonists or soluble receptors, analogous to 
those for IL-I, TNF and some other cytokines [29], are 
unlikely to be found for IL-S. The cloning of two dis- 
tinct cDNAs is in agreement with the biochemical evi- 
dence for two IL-8 receptors. Information on the se- 
quence of the receptors identified by crosslinking must 
now be obtained. 
5.2. Structurul determinants of receptor binding 
The 3D structure of the IL-8 dimer bears some resem- 
blance with the antigen-binding domain of the HLA 
molecule. Since the groove that binds the antigen is 
formed by two a-helices it was thought that the C- 
terminal helices of the IL-8 dimer constitute the recep- 
tor binding site. Recent structure-,activity relation stud- 
ies, however, indicate that IL-8 binds at the N-terminus 
[30]. Using chemically synthesized analogs, we have 
found that removal of the entire C-terminal domain 
decreased, but did not suppress biological activity. In 
contrast, no receptor binding or neutrophil activation 
was observed when the N-terminal sequence Glu-Leu- 
Arg that precedes the first cysteine was deleted. All 
three residues, Arg in particular, are highly sensitive to 
modification. The role of Glu-Leu-Arg is also empha- 
sized by a recent mutagenesis study showing that re- 
placement of these residues by alanine results in loss of 
activity [31]. In this context it is interesting to note that 
the Glu-Leu-Arg motif is common to all IL-8 related 
chemotactic ytokines, but is not found in platelet fac- 
tor 4 and IPIO (Fig. 3). Short peptides containing the 
Glu- Leu-Arg motif are inactive, suggesting that either 
a particular conformation of the tripeptide, or interac- 
tions of other domains of the IL-8 molecule with the 
100 
receptor are required. Since nuclear magnetic resonance 
spectroscopy, shows that the N-terminus has a high de- 
gree of flexibility, the conformation of the entire protein 
appears to be important. This is in agreement with the 
observation that IL-8 is inactivated when the disulfide 
bonds are eliminated either by reduction or by substitu- 
tion of the cysteines. 
6. PATHOPHYSIOLOGY 
The ability to attract and activate neutrophils quali- 
fied IL-8 from the beginning as an inflammatory medi- 
ator [I]. Meanwhile thi.s hypothesis has been amply ver- 
ified, in particular by the study of inflammatory skin 
and joint diseases. Considerable IL-8 immunoreactivity 
is found in the skin of patients with psoriasis and palmo- 
plantar pustulosis [32-341, where expression of IL-8 
mRNA is prominent in keratinocytes [35]. IL-8 accumu- 
lates in the synovial fluid of arthritic joints [16,36] and 
is released by stimulated synovial cells [37] and chon- 
drocytes [38]. Mononuclear cells from the blood or syn- 
ovial fluid of patients with rheumatoid arthritis release 
much higher amounts of IL-8 than cells from healthy 
controls after stimulation with LPS, IL-l, TNF and 
immune complexes [ 161. 
IL-8 appears to be particularly suited for a role in 
inflammation and host defence. As a product of differ- 
ent types of cells it can arise irl any tissue when the levels 
of IL-I and/or TNF (which are powerful inducers) are 
enhanced. Generation of IL-8 can be expected upon 
infection, ischemia, trauma, and other disturbances of 
tissue homeostasis, ince IL-1 and TNF levels are ele- 
vated. In all these conditions IL-8 is likely to be the 
main cause of the local accumulation of neutrophils [ 1, 
133. Resisrmce to irzuctivation arzd slow clearance, as 
shown by the long-lasting chemoattractant effect after 
intradermal injection [lo], suggests that IL-8 persists in 
active form within the immediate nvironment of the 
cells from which it is released. Other chemoattractants 
like fMet-Leu-Phe, CSa, LTB4 and PAF, by contrast, 
act more transiently because they are inactivated rap- 
idly by oxidation or hydrolysis [lo]. 
Most remarkable is the high number of related cyto- 
kirzes. Five distinct chemotactic proteins have been 
identified that share structural and biological similarity 
with IL-S, and bind to the IL-8 receptors. Redundancy 
strongly suggests that these cytokines are relevant in 
physiology and pathology. IL-8 and its related cytoki- 
nes can be expressed concomitantly by cells that are 
stimulated with lL-l or TNF. They are likely to concur 
in recruiting neutrophils, but may also fulfill additional, 
still unknown functions. 
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